Related Experiment Video
Updated: May 26, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Developing treatments for impaired cognition in schizophrenia
Michael J Minzenberg1, Cameron S Carter
1Department of Psychiatry and Center for Neuroscience, University of California Davis School of Medicine, Sacramento, CA 95817, USA. michael.minzenberg@ucdmc.ucdavis.edu
Trends in Cognitive Sciences
|December 20, 2011
Summary
Treatments for cognitive deficits in schizophrenia are emerging, including new drugs and technologies. Integrating these approaches may improve outcomes for patients suffering from this brain disorder.
Area of Science:
- Neuroscience
- Psychiatry
- Clinical Psychology
Background:
- Schizophrenia is a severe brain disorder with significant public health implications.
- Cognitive deficits, not psychotic symptoms, are key predictors of clinical outcomes in schizophrenia.
- Currently, no definitive treatments exist for cognitive impairment in schizophrenia.
Purpose of the Study:
- To review the current status of treatment development for cognitive deficits in schizophrenia.
- To explore various therapeutic strategies, including pharmacological and non-pharmacological interventions.
Main Methods:
- Review of existing literature on pharmacological treatments targeting neurotransmitter systems.
- Examination of novel technological interventions like transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS).
- Analysis of psychological therapies, including computer-based cognitive training.
Main Results:
- Pharmacological targets within multiple neurotransmitter systems show promise for treating cognitive deficits.
- Non-invasive brain stimulation techniques (TMS, tDCS) are being investigated as potential cognitive enhancers.
- Cognitive training programs demonstrate potential benefits for improving cognition in schizophrenia.
Conclusions:
- Multiple promising avenues exist for treating cognitive impairment in schizophrenia.
- The integration of pharmacological, technological, and psychological approaches may offer the most effective future treatment strategy.
- Further research and development are crucial to optimize these treatments for patient benefit.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:30Negative and Cognitive Symptoms of Schizophrenia
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...